최신 팟캐스트 지식.

Podwise가 처리한 새 에피소드. 검색하고 훑어보고 앱에서 이어 보세요.

방금 요약됨

재생하기 전에 각 에피소드가 다루는 내용을 읽어보세요.

万物生长FM10월 26일

头对头赢过K药这两年，康方生物怎么了？E.252

AI 요약 康方生物及其核心药物依沃西单抗的临床表现与全球化进程，是当前创新药领域的核心议题。依沃西单抗通过双特异性抗体机制，在多项中国临床试验（如 HARMONi-2 和 HARMONi-6）中展现出优于传统 PD-1 抑制剂的疗效，成功改写了肺癌治疗标准。然而，其全球多中心临床试验面临人群差异、统计学门槛及执行一致性等多重挑战，导致市场预期出现显著波动。尽管与 Summit…

ASCO
依沃西单抗
PD-1

01:03:13Chinese요약 · 스크립트

Alex Volkov from ThursdAI11월 13일

ThursdAI Nov 12 - No more Jensen at Nvidia, Gemini 4 Hydrogen, Fable 5.2, software factories & more

AI 요약 Jensen Huang’s sudden resignation as Nvidia CEO dominates the industry conversation, sparking intense speculation regarding the underlying causes, ranging from alleged Chinese espionage to internal leadership transitions. Amidst this turmoil, the AI landscape continues to evolve…

Jensen Huang
Gemini 4
Software Factory

English요약 · 스크립트

AGI原野 | 技术创业现场11월 11일

EP21. Manus的出海历险：一家公司的选择，如何成为一个时代的注脚

AI 요약 Manus 的发展历程折射出 AI 创业公司在复杂地缘政治与监管博弈中的生存困境。作为一家 AI Agent 产品公司，Manus 在获得硅谷风投 Benchmark 投资后，迅速遭遇美国 “反向 CFIUS” 审查，被迫将总部迁至新加坡以规避风险。随后，Meta 对其发起的收购引发了中国商务部关于技术出口的国家安全审查，最终导致交易撤销并由中资机构回购。这一系列跌宕起伏的资本运作与监管干预，不仅揭示了中美科技竞赛下 “科技回流” 的政策暗线，也为寻求全球化发展的创业者提供了关于政治敏感性与合规边界的深刻警示。Manus 的经历证明，在 AI…

Manus
蝴蝶效应
DeepSeek

45 minChinese요약 · 스크립트

Beyond The Prompt - How to use AI in your company11월 11일

Whatever You Might Think About AI, You Must Feel Awe: Pulitzer Finalist Robert Wright on “The God Test”

AI 요약 Artificial intelligence is evolving into a potential "global brain," a superintelligence that may eventually possess governing authority. This technological shift demands a new, cohesive international framework to manage existential risks, such as the development of bioweapons…

The God Test
Awe Spectrum
Global Brain

00:51:31English요약 · 스크립트

Equity11월 11일

How backlash and red tape continue to slow data centers post-Blue Wave

AI 요약 Data center development faces a significant disconnect between projected capacity and actual infrastructure delivery, driven by speculative "large load" queues that often overestimate realistic build-outs by an order of magnitude. While hyperscalers and AI firms scramble for…

Anthropic
Hyperscaler
ERCOT

33 minEnglish요약 · 스크립트

万物生长FM11월 12일

艾伯维，何以成为免疫之王|跨国药企简史E.257

AI 요약 艾伯维通过精密的专利丛林构建、诉讼和解及 PBM 反点机制，成功化解了 “药王” 修美乐专利到期带来的巨大冲击。在核心产品面临专利悬崖时，公司利用深厚的现金流优势，通过并购利生奇珠单抗和乌帕替尼等临床后期资产，迅速完成了第二增长曲线的接棒。这种以现金流为驱动的商业模式，通过优化给药方式和拓展适应症，将新药迅速推向百亿销售规模。艾伯维的成功不仅在于分子的选择，更在于其强大的组织执行力，即在旧产品盈利期内主动完成处方转移，并利用医美与神经科学业务的稳定性对冲免疫领域的周期性风险，展现了跨国药企在专利生命周期管理中的极致策略。